vTv Therapeutics and OnKure part ways, dissolving pivotal cellular drug agreement
vTv Therapeutics, a clinical-stage biopharmaceutical company known for its innovative approach in diabetes treatment, and OnKure Therapeutics, an oncology-focused pharmaceutical company, have announced the termination of their global drug licensing agreement. This partnership, established to leverage vTv’s expertise in small molecule drugs targeting cancer cells, is now dissolved, signaling a major shift for both companies […]
